Groundbreaking
science for discovering
targeted small molecule
therapeutic drugs

Groundbreaking
science for discovering
targeted small molecule
therapeutic drugs

Innovative Molecular Therapy Allinky Biopharma

About Allinky

What we do

We are a team of multidisciplinary scientists pioneering the discovery and development of novel oral allosteric inhibitors as therapeutic agents to address unmet medical needs in oncology and chronic inflammation.

This strategy has led us to design and develop a world’s first-in-class targeted small molecule therapeutic, an oral inhibitor of IL-1β production. It represents a critical breakthrough for chronic difficult-to-treat diseases.

Why we stand out

Approach

We design and develop targeted small molecule therapeutic drugs specifically designed to modulate the function of molecular mediators that play a critical role in the onset and progression of chronic inflammation and cancer.

Innovation

Our trailblazing research has birthed the first-in-class oral inhibitor of IL-1β production, a small molecule that may be a game-changer in the treatment of  IL-1β-related diseases that currently lack effective treatment options.

Pipeline

Encompassing a diverse array of cutting-edge small molecule allosteric inhibitors targeting key pathways involved in challenging diseases, our portfolio reflects our dedication to providing impactful and transformative therapies to patients in need.

Allinky is driven by science, research, and innovation.
Our dedication lies in enhancing the lives of patients through the development of new, effective therapies, offering hope and improving outcomes.

Our latest news

Stay informed with our
most recent news

Allinky will attend AseBio Investor Day 2024

Allinky will attend AseBio Investor Day 2024

Allinky will attend the next edition of AseBio Investor Day , which will be held in Donostia-San Sebastian on May 15th. AseBio Investor Day…

European patent granted to Allinky

On December 20th, 2023, the European Patent Office published the mention of the grant of the European Patent for the invention 'PYRIDIN-SULFONAMIDE…
Allinky executes a new capital increase of 2 million euros

Allinky executes a new capital increase of 2 million euros

Last December 2023, Allinky executed a new capital increase of €2 million to conclude the preclinical evaluation of its most advanced candidate,…

Contact Us

Your enquiries are important to us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.